Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.49 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.43 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22011275 | 1.00 | MAPK1 (0.49) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21961988 | 1.00 | MAPK1 (0.49) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21961961 | 0.90 | MAPK1 (0.60) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21961960 | 0.90 | MAPK1 (0.60) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL22011156 | 0.90 | MAPK1 (0.60) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL22011151 | 0.88 | MAPK1 (0.48) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21961966 | 0.87 | MAPK1 (0.50) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21961967 | 0.87 | MAPK1 (0.50) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21962015 | 0.87 | MAPK1 (0.50) | MAPK1MAP4K1IL2GSK3BCLK1 | |
| SCHEMBL21962022 | 0.83 | MAPK1 (0.50) | MAPK1MAP4K1IL2GSK3BCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428416-B2 | ERK inhibitors and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| EP-3880677-A1 | ERK INHIBITORS AND USES THEREOF | California Institute of Technology (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102686-A1 | ERK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | MAPK1 11/4885MAP4K1 12/4885IL2 3843/4885 |
| US-12428416-B2 | ERK inhibitors and uses thereof | MAPKAPK2, MAPK3, MAP4K2 | MAPK1 11/4885MAP4K1 12/4885IL2 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.